A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening.
A large spectrum of methods has been used in both routine and scientific studies of the hemostatic system. The particular interest of the investigators has been focused on methods simultaneously evaluating clotting and fibrinolysis processes. The aim of the present study was to develop an optical method for overall evaluation of clot formation and lysis (CL-test) that could be used in drug screening. The CL-test was performed in citrate plasma diluted with Tris-buffered saline. Thrombin was applied for plasma clotting (0.5 IU/ml), while tissue plasminogen activator (60 ng/ml) was used for fibrinolysis activation. Clot formation and lysis were monitored in thermostatic conditions (37 degrees C) as a continuous record of transmittance change. By means of own computer program, kinetic parameters of the processes studied and plasma overall clot formation and fibrinolysis potential, expressed as the area under the clotgeneration and fibrinolysis curves, were calculated. The CL-test was developed and checked by evaluation of the effect, on clot formation and lysis, of various concentrations of acetylsalicylic acid (a drug that affects hemostasis), aprotinin (fibrinolysis activator) and venoruton (fibrinolysis inhibitor). The obtained results confirmed that the test we propose for monitoring clot formation, stabilization and lysis is sensitive and enables precise estimation of the processes studied. In our opinion, it can be a useful tool in drug screening investigations.
Kostka
Barbara
B
Department of Pharmaceutical Biochemistry, Medical University of Lodz, Lodz, Poland.
Para
Jadwiga
J
Sikora
Joanna
J
D000933:Antifibrinolytic Agents / Q000378:metabolism / Q000494:pharmacology*; D001241:Aspirin / Q000378:metabolism / Q000494:pharmacology; D001780:Blood Coagulation Tests / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D016903:Drug Monitoring / Q000379:methods; D005337:Fibrin / Q000187:drug effects / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects / Q000502:physiology; D005343:Fibrinolytic Agents / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D009098:Multiphasic Screening / Q000379:methods; D012107:Research Design; D012984:Software; D013917:Thrombin / Q000378:metabolism; D015912:Thrombolytic Therapy / Q000295:instrumentation / Q000379:methods; D013927:Thrombosis / Q000188:drug therapy* / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000378:metabolism / Q000494:pharmacology
D000933:Antifibrinolytic Agents; D005343:Fibrinolytic Agents; D005337:Fibrin; D013917:Thrombin; D010959:Tissue Plasminogen Activator; D001241:Aspirin